Sustainalytics
Stories
-
Samsung Biologics achieves 'Negligible Risk' rating in Sustainalytics ESG assessment
Samsung Biologics received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. The result places the company among the top 0.5% of companies assessed in the pharmaceuticals industry.